Avanza Fonder Ab Arcellx, Inc. Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Arcellx, Inc. stock. As of the latest transaction made, Avanza Fonder Ab holds 2,398 shares of ACLX stock, worth $160,689. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,398Holding current value
$160,689% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
206Shares Held
44.1MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$268 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$261 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$251 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$236 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$165 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...